Histologic comparison of tumor necrosis factor-? inhibitor–induced psoriasis and psoriasis vulgaris - 19/06/20
Abstract |
Background |
Tumor necrosis factor-α inhibitor (TNFi)–induced psoriasis is a paradoxic reaction characterized by the development of a psoriasiform rash that mimics idiopathic psoriasis subtypes both clinically and histologically. Few studies have investigated the histologic features of TNFi-induced psoriasis skin lesions, and most of these are limited by inclusion of few specimens.
Objective |
We aimed to characterize histologic features of TNFi-induced psoriasis and identify histologic differences between TNFi-induced psoriasis and idiopathic psoriasis.
Methods |
We characterized 60 biopsy specimens obtained from 47 unique patients at a single tertiary care referral center between 2004 and 2016 who developed TNFi-induced psoriasis, and we compared histologic features to those of 85 biopsy specimens from a control group of 85 patients with idiopathic psoriasis.
Results |
The most common histologic reaction pattern in TNFi-induced psoriasis biopsy specimens was psoriasiform (80.0%). Five histologic parameters were significantly different in TNFi-induced psoriasis biopsy specimens compared with idiopathic psoriasis biopsy specimens: at least 3 dermal eosinophils per histologic section, neutrophils in the stratum corneum, neutrophils in the epidermis, papillary plate thinning, and absence of parakeratosis.
Limitations |
Inability to exclude lesion selection bias as a potential reason for some significant histologic differences.
Conclusions |
This study supports the idea that histologic differences exist between TNFi-induced psoriasis and idiopathic psoriasis may help distinguish between these conditions, especially for dermal eosinophil counts of 3 or greater.
Le texte complet de cet article est disponible en PDF.Key words : eosinophils, histology, parakeratosis, psoriasis vulgaris, TNF-α inhibitor–induced psoriasis
Abbreviations used : IL, INF, INF-α, pDC, TNF-α, TNFi
Plan
| Funding sources: None. |
|
| Disclosure: Dr Fernandez is an investigator for Pfizer, Corbus, Mallinckrodt, and Novartis Pharmaceuticals and receives personal research support from Mallinckrodt and Novartis; honoraria from AbbVie, UCB, Novartis, and Mallinckrodt for consulting and advisory board participation; and honoraria from AbbVie, Novartis, and Mallinckrodt for teaching and speaking. Mr Hu and Drs Billings and Yan have no conflicts of interest to declare. |
|
| IRB approval status: Reviewed and approved by the Cleveland Clinic IRB (approval #13-701). |
Vol 83 - N° 1
P. 71-77 - juillet 2020 Retour au numéro
Article précédent
- Granuloma annulare skin profile shows activation of T-helper cell type 1, T-helper cell type 2, and Janus kinase pathways
- Michelle S. Min, Jianni Wu, Helen He, Juan Luis Sanz-Cabanillas, Ester Del Duca, Ning Zhang, Yael Renert-Yuval, Ana B. Pavel, Mark Lebwohl, Emma Guttman-Yassky
- A prospective cohort study of condensed low-dose total skin electron beam therapy for mycosis fungoides: Reduction of disease burden and improvement in quality of life
- Andrew Song, Ashley Gochoco, Tingting Zhan, Joya Sahu, Onder Alpdogan, Pierluigi Porcu, Neda Nikbakht, Wenyin Shi
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?